20-Week Study of Clinical Outcomes of Over-the-Counter COVID-19 Prophylaxis and Treatment
Margolin et al.
, 20-Week Study of Clinical Outcomes of Over-the-Counter COVID-19 Prophylaxis and Treatment
, Journal of Evidence-Based Integrative Medicine, doi:10.1177/2515690X211026193
Retrospective 113 outpatients, 53 (patient choice) treated with zinc, quercetin, vitamin C/D/E, l-lysine, and quina, showing lower cases with treatment. Results are subject to selection bias and limited information on the groups is provided. See [journals.sagepub.com]
risk of case, 94.4% lower, RR 0.06, p = 0.003, treatment 0 of 53 (0.0%), control 9 of 60 (15.0%), NNT 6.7, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of COVID-19 or flu-like illness, 81.1% lower, RR 0.19, p = 0.01, treatment 2 of 53 (3.8%), control 12 of 60 (20.0%), NNT 6.2.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Margolin et al., 6 Jul 2021, retrospective, USA, peer-reviewed, 5 authors, this trial uses multiple treatments in the treatment arm (combined with zinc, vitamin C/D/E, l-lysine, and quina) - results of individual treatments may vary.
Abstract: Original Manuscript
20-Week Study of Clinical Outcomes of
Over-the-Counter COVID-19 Prophylaxis
Journal of Evidence-Based Integrative Medicine
Volume 26: 1-13
ª The Author(s) 2021
Article reuse guidelines:
Leon Margolin, MD, PhD1 , Jeremy Luchins, PhD1 ,
Daniel Margolin, Bsc1, Michelle Margolin1, and Sanford Lefkowitz, MSc1
Objectives and Setting. As the lethal COVID-19 pandemic enters its second year, the need for effective modalities of alleviation
remains urgent. This includes modalities that can readily be used by the public to reduce disease spread and severity. Such
preventive measures and early-stage treatments may temper the immediacy of demand for advanced anti-COVID measures
(drugs, antibodies, vaccines) and help relieve strain also on other health system resources. Design and Participants. We present
results of a clinical study with a multi-component OTC “core formulation” regimen used in a multiply exposed adult population.
Analysis of clinical outcome data from our sample of over 100 subjects comprised of roughly equal sized regimen-compliant
(test) and non-compliant (control) groups meeting equivalent inclusion criteria demonstrates a strong statistical significance in
favor of use of the core formulations. Results. While both groups were moderate in size, the difference between them in outcomes
over the 20-week study period was large and stark: Just under 4% of the compliant test group presented flu-like symptoms, but
none of the test group was COVID-positive; whereas 20% of the non-compliant control group presented flu-like symptoms,
three-quarters of whom (15% overall of the control group) were COVID-positive. Conclusions. Offering a low cost, readily
implemented anti-viral approach, the study regimen may serve, at the least, as a stopgap modality and, perhaps, as a useful tool in
combatting the pandemic.
COVID-19, SARS-CoV-2, prophylaxis, early-stage treatment, OTC, zinc, ionophores, immunity enhancement, regimen
Received March 11, 2021. Received revised May 04, 2021. Accepted for publication May 30, 2021.
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.